Julie Deckers is a Senior Scientist in Preclinical Product Development at argenx, a leading biotechnology company specializing in the discovery and development of innovative antibody-based therapies. Argenx created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies aimed at addressing unmet medical needs.
At the Festival of Biologics Basel 2025, Europe's Largest Biologics Event, Julie will share insights on how antibody engineering could successfully maxamize clearance of abundant targets.